Please assess the completion status of the following clinical trial:

Trial Title: Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven diagnosis of SCLC;~* Limited or extensive-stage disease in patients who have received a single chemotherapy regimen or combined modality (chemotherapy + chest radiotherapy) regimen and relapsed after completion of first-line chemotherapy (sensitive relapse);~* Age \>/= 18 years;~* ECOG Performance Status 0-2;~* Life expectancy of at least 12 weeks;~* Measurable lesions according to RECIST criteria;~* Adequate cardiac, hepatic, renal, and bone marrow function;~* Written informed consent.~Exclusion Criteria:~* Prior treatment with an HDAC inhibitor;~* Symptomatic and/or unstable pre-existing brain metastases;~* Superior Vena Cava Syndrome;~* Spinal cord compression;~* Severe or uncontrolled medical diseases (Hypertension, diabetes, congestive heart failure, myocardial infarction within 6 months of study, chronic renal disease, or active uncontrolled infections);~* Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ;~* Pregnant or breastfeeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vorinostat/Topotecan (Type: EXPERIMENTAL): Vorinostat/topotecan dose escalation regimen. vorinostat is administered orally once a day for 7 to 14 consecutive days, according to the dose level.Topotecan is administered I.V. for 5 consecutive days every three weeks.~Vorinostat dose levels go from 300 mg/day for 7 days to 400 mg/day for 14 days. Topotecan dose levels go from 1,2 mg/m2 to 1,5 mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).